GleamWall
中文EN

ZLAB Zai Lab Ltd

Pharmaceutical Preparations · Nasdaq · SEC CIK 1704292 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY0.0%
TTM net income YoY4.1%
TTM EPS YoY5.3%
Revenue 3-yr CAGR18.8%
Net income 3-yr CAGR—

Margins

Gross margin54.7%
Operating margin-63.0%
Net margin-44.9%
FCF margin-37.0%
EBITDA margin-60.1%

Returns

ROE-30.0%
ROA-18.2%
ROIC (approx.)-779.4%
Asset turnover0.40x

Leverage & solvency

Liabilities / assets45.0%
Debt / equity0.00x
Current ratio2.04x
Interest coverage-45.16x

Cash quality & payout

Operating cash flow / net income0.80x
Accruals ratio-3.6%
Payout ratio—
Capex / revenue0.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$108.21M$106.31M$99.61M$127.60M$116.09M$109.98M$106.49M$109.07M
Cost of revenue$51.30M$48.16M$38.31M$62.30M$46.76M$43.00M$38.45M$41.78M
Gross profit$56.90M$58.15M$61.30M$65.30M$69.33M$66.97M$68.03M$67.29M
R&D expense$49.81M$61.77M$65.59M$61.63M$47.93M$50.61M$60.73M$52.25M
SG&A expense$70.07M$72.87M$65.07M$73.04M$70.11M$71.04M$63.42M$82.62M
Operating income-$62.98M-$76.49M-$69.39M-$69.41M-$48.82M-$54.90M-$56.31M-$67.89M
Interest expense$1.58M$1.59M$1.64M$1.36M$1.40M$1.26M$1.19M$904,000
Pretax income-$48.01M-$51.85M-$49.58M-$53.34M-$35.96M-$40.73M-$48.44M-$81.68M
Income tax-$1.87M-$1.02M$1.44M-$2.93M$0$0$0$0
Net income-$46.14M-$50.83M-$51.02M-$50.41M-$35.96M-$40.73M-$48.44M-$81.68M
EBITDA-$60.68M-$74.09M-$65.44M-$65.49M-$46.42M-$52.59M-$52.85M-$64.86M
EPS (basic)-0.04-0.05-0.05—-0.03-0.04-0.04—
EPS (diluted)-0.04-0.05-0.05—-0.03-0.04-0.04—
Weighted avg. shares (diluted)1.12B1.12B1.11B—1.10B1.09B1.08B—
Balance sheet
Cash & equivalents$549.66M$607.52M$651.32M$679.57M$717.15M$732.16M$757.26M$449.67M
Short-term investments$10.00M$10.00M$10.00M$10.00M$0$0$0$330.00M
Receivables$65.30M$69.59M$54.07M$106.12M$85.38M$88.50M$76.56M$85.18M
Inventory$85.29M$90.89M$85.96M$74.75M$67.14M$61.70M$53.05M$39.88M
Current assets$864.40M$914.04M$944.73M$1.02B$1.03B$1.03B$1.04B$1.05B
PP&E, net$46.08M$46.43M$47.07M$47.39M$48.87M$50.16M$49.65M$47.96M
Intangibles$85.30M$85.77M$75.76M$76.14M$55.28M$56.52M$56.20M$56.03M
Total assets$1.02B$1.07B$1.10B$1.17B$1.16B$1.16B$1.17B$1.19B
Current liabilities$424.25M$428.58M$392.98M$416.17M$359.77M$331.50M$319.81M$299.38M
Short-term debt$252.37M$238.10M$213.82M$204.53M$203.03M$174.51M$173.41M$131.71M
Total liabilities$460.62M$467.76M$433.76M$456.88M$399.00M$372.37M$362.58M$344.86M
Shareholders' equity$563.28M$607.04M$661.98M$715.50M$759.95M$791.74M$810.75M$840.90M
Shares outstanding1.12B1.12B1.11B1.11B1.11B1.10B1.08B1.08B
Cash flow statement
Operating cash flow-$57.87M-$63.41M-$11.91M-$26.02M-$32.04M-$31.02M-$61.70M-$55.77M
Capital expenditure$947,000$1.31M$1.20M$677,000$3.00M$2.88M$1.53M$2.60M
Free cash flow-$58.81M-$64.72M-$13.11M-$26.70M-$35.05M-$33.91M-$63.23M-$58.37M
Investing cash flow-$12.68M-$1.42M-$22.29M-$11.30M-$4.05M-$2.92M$326.13M-$347.75M
Financing cash flow$14.05M$18.70M$5.57M-$430,000$20.79M$8.85M$43.14M$237.81M
Depreciation & amortization$2.30M$2.40M$3.94M$3.92M$2.40M$2.30M$3.46M$3.03M
Stock-based compensation$11.34M$12.13M$13.52M$15.90M$16.92M$16.97M$15.80M$17.24M

Free plan shows the latest 8 periods; Pro shows all 30 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.